TriMix Injection Recalled Due to Lack of Sterility Assurance
Northern VA Compounders is recalling TriMix Injection due to lack of sterility assurance. The compounded injectable medication may not meet required sterility standards.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall with no reported hospitalizations or illnesses. The recall involves a risk-of-harm product (compounded injectable) where injury has not yet been reported, meeting the criteria for a High severity rating.
Plain-English summary
Northern VA Compounders PLLC is recalling TriMix Injection (PGE1/Papaverine HCl/Phentolamine Mesylate), a compounded injectable medication supplied in 2.5 mL multiple-dose vials. The affected lot is #11212022@7, with an expiration date of January 5, 2023. A total of four vials of this prescription medication were distributed nationwide.
The recall was initiated due to lack of assurance that the product meets required sterility standards for injectable medications. Non-sterile injectables could pose a risk of infection or other complications if administered to patients.
The affected product was distributed nationwide to healthcare providers and pharmacies. Patients and healthcare providers who have this medication should contact their pharmacy or healthcare provider.
All remaining vials from Lot #11212022@7 should be returned to the pharmacy or manufacturer immediately and not used. Patients who have received injections from this lot should consult with their healthcare provider regarding any health concerns.
The recalled product
- Product
- TriMix Injection (PGE1/Papaverine HCl/Phentolamine Mesylate) 100mcg/30mg/3mg/mL INJECTABLE, 2.5 mL Multiple-Dose vials, Rx Only, Compounded by: Akina Pharmacy, 23475 Rock Haven Way Suite 105, Sterling, VA 20166.
- Manufacturer
- Northern VA Compounders PLLC
- Category
- Drug — Compounded Injectable
- Hazard
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 11212022@7
- Exp 1/5/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01